Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.62 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | MMP3 | P08254 | 1/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.60 |
| ▸ | MMP13 | P45452 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6885409 | 1.00 | FFAR1 (0.74) | FFAR1LMNAKMT2AMAPTTDP1 | |
| SCHEMBL10464668 | 1.00 | FFAR1 (0.74) | FFAR1LMNAKMT2AMAPTTDP1 | |
| SCHEMBL12008950 | 0.87 | FFAR1 (0.86) | FFAR1LMNAKMT2AMAPTMEN1 | |
| SCHEMBL20534434 | 0.86 | KDR (0.66) | FFAR1KMT2AMAPTMEN1POLB | |
| SCHEMBL20534435 | 0.86 | KDR (0.66) | FFAR1KMT2AMAPTMEN1POLB | |
| SCHEMBL12006896 | 0.85 | FFAR1 (1.00) | FFAR1LMNAKMT2AMAPTTDP1 | |
| SCHEMBL1901692 | 0.85 | PTPN22 (0.61) | FFAR1KMT2AMAPTPTPN12PTPN22 | |
| SCHEMBL1901689 | 0.85 | PTPN22 (0.61) | FFAR1KMT2AMAPTPTPN12PTPN22 | |
| SCHEMBL1901690 | 0.85 | PTPN22 (0.61) | FFAR1KMT2AMAPTPTPN12PTPN22 | |
| SCHEMBL13056346 | 0.83 | PTPN22 (0.67) | KMT2AMAPTPTPN12PTPN22MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298390-A1 | INHIBITION OF LETHAL FACTOR PROTEASE ACTIVITY FROM ANTHRAX TOXIN | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298390-A1 | INHIBITION OF LETHAL FACTOR PROTEASE ACTIVITY FROM ANTHRAX TOXIN | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-11-25 | — | — | US | disclosed |
| US-7718680-B2 | Inhibition of lethal factor protease activity from anthrax toxin | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718680-B2 | Inhibition of lethal factor protease activity from anthrax toxin | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-05-18 | — | — | US | disclosed |
| US-20080033025-A1 | Inhibition of lethal factor protease activity from anthrax toxin | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-02-07 | — | — | US | disclosed |
| US-20080033025-A1 | Inhibition of lethal factor protease activity from anthrax toxin | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-02-07 | — | — | US | disclosed |
| US-6673816-B1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | Esswein, Angelika (DE) | 2004-01-06 | — | — | US | disclosed |
| US-20030032813-A1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | ANGELIKA ESSWEIN, WOLFGANG SCHAEFER, AND KONRAD HONOLD | 2003-02-13 | — | — | US | disclosed |
| EP-1117655-A1 | RHODANINE CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS | Esswein, Angelika (DE) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018747-A1 | RHODANINE CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS | ROCHE DIAGNOSTICS GMBH (DE) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032813-A1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | NR1H4, NR1D1, NR1I2 | FFAR1 239/4885LMNA 3168/4885KMT2A 1995/4885 |
| US-20100298390-A1 | INHIBITION OF LETHAL FACTOR PROTEASE ACTIVITY FROM ANTHRAX TOXIN | APAF1, ANTXR2, SERPINB1 | FFAR1 3748/4885LMNA 1087/4885KMT2A 3456/4885 |
| US-20080033025-A1 | Inhibition of lethal factor protease activity from anthrax toxin | APAF1, ANTXR2, SERPINB1 | FFAR1 3748/4885LMNA 1087/4885KMT2A 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.